Co-development Terms & Agreements in Pharma, Biotech and Diagnostics
Published: Aug 2014 | Publisher: Current Partnering | Pages: 695SUMMARY
The Co-development R&D Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-development deals and agreements entered into by the worlds leading healthcare companies
TABLE OF CONTENTS
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in co-development dealmaking
2.1. Introduction
2.2. Definition of co-development deals
2.3. Success factors for co-development deals
2.4. When co-development can be useful
2.5. Attributes of co-development deals
2.6. Aligning partners to make the co-development work
2.7. Trends in co-development deals since 2009
2.8. Option to co-develop
2.9. The future of co-development deals
Chapter 3 – Overview of co-development deal structure
3.1. Introduction
3.2. Pure versus multi-component co-development deals
3.3. Pure co-development agreement structure
3.3.1. Example co-development agreements
3.3.1.a. Case study 1: Ambrx – Zhejiang Medicine – June 2013
3.3.1.b. Case study 2: UniQure - Chiesi – July 2013
Chapter 4 – Leading co-development deals
4.1. Introduction
4.2. Top co-development deals by value
4.3. Most active co-development dealmakers
4.4. Bigpharma co-development deal activity
Chapter 5 – Bigpharma co-development deals
5.1. Introduction
5.2. How to use co-development deals
5.3. Company co-development agreement listings
Chapter 6 – Bigbiotech co-development deals
6.1. Introduction
6.2. How to use co-development deals
6.3. Company co-development agreement listings
Chapter 7 – Co-development contract directory 2009-2014
7.1. Introduction
7.2. Company A-Z
7.3. By therapy area
Anaesthetics
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Genetic disorders
Gynecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Psychiatry
Public health
Respiratory
7.4. By stage of development at signing
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
7.5. By technology area
Antibodies
Assays
Biological compounds
Biomarkers
Biomaterials
Biosimilars/Bio-betters
Clinical testing
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Equipment
Gene therapy
Genomics
Industrial chemicals
Nanotechnology
Natural product
Oligonucleotide
Peptides
Processes
Proteomics
Recombinant DNA
Research services
RNA therapeutics
Screening
Small molecules
Software tools
Vaccines
Appendix
Appendix 1 – Co-development references
Appendix 2 – Resources
Appendix 3 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Order Form – Upgrades to subscription access products
Recent report titles from CurrentPartnering
Order Form – Reports
Separate appendix file supplied for:
Appendix 1 – Co-development dealmaking - by financial disclosure
Appendix 2 – Co-development dealmaking - by companies A-Z
Appendix 3 – Co-development dealmaking - by stage of development
Appendix 4 – Co-development dealmaking - by therapeutic target
Appendix 5 – Co-development dealmaking - by technology type
TABLE OF FIGURES
Figure 1: Definition of co-development
Figure 2: Situations where co-development can prove useful
Figure 3: Key components of a co-development deal
Figure 4: Issues in implementing co-development agreements
Figure 5: Trends in co-development deal announcements, 2009-2014
Figure 6: Co-development deals signed at each phase of development, 2009-2013
Figure 7: Co-development agreements – what should a contract include?
Figure 8: Components of the co-development deal structure
Figure 9: Top co-development deals by value since 2009
Figure 10: Most active co-development dealmakers 2009-2014
Figure 11: Bigpharma – top 50 – Co-development deals 2007 to 2013
Figure 12: Bigpharma co-development deal frequency - 2009 to 2014
Figure 13: Online partnering resources
Figure 14: Deal type definitions
Chapter 1 – Introduction
Chapter 2 – Trends in co-development dealmaking
2.1. Introduction
2.2. Definition of co-development deals
2.3. Success factors for co-development deals
2.4. When co-development can be useful
2.5. Attributes of co-development deals
2.6. Aligning partners to make the co-development work
2.7. Trends in co-development deals since 2009
2.8. Option to co-develop
2.9. The future of co-development deals
Chapter 3 – Overview of co-development deal structure
3.1. Introduction
3.2. Pure versus multi-component co-development deals
3.3. Pure co-development agreement structure
3.3.1. Example co-development agreements
3.3.1.a. Case study 1: Ambrx – Zhejiang Medicine – June 2013
3.3.1.b. Case study 2: UniQure - Chiesi – July 2013
Chapter 4 – Leading co-development deals
4.1. Introduction
4.2. Top co-development deals by value
4.3. Most active co-development dealmakers
4.4. Bigpharma co-development deal activity
Chapter 5 – Bigpharma co-development deals
5.1. Introduction
5.2. How to use co-development deals
5.3. Company co-development agreement listings
Chapter 6 – Bigbiotech co-development deals
6.1. Introduction
6.2. How to use co-development deals
6.3. Company co-development agreement listings
Chapter 7 – Co-development contract directory 2009-2014
7.1. Introduction
7.2. Company A-Z
7.3. By therapy area
Anaesthetics
Cardiovascular
Central Nervous System
Dermatology
Gastrointestinal
Genetic disorders
Gynecology
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Oncology
Ophthalmics
Orphan disease
Psychiatry
Public health
Respiratory
7.4. By stage of development at signing
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
7.5. By technology area
Antibodies
Assays
Biological compounds
Biomarkers
Biomaterials
Biosimilars/Bio-betters
Clinical testing
Devices
Diagnostics
Discovery tools
DNA probes
Drug delivery
Enabling technology
Equipment
Gene therapy
Genomics
Industrial chemicals
Nanotechnology
Natural product
Oligonucleotide
Peptides
Processes
Proteomics
Recombinant DNA
Research services
RNA therapeutics
Screening
Small molecules
Software tools
Vaccines
Appendix
Appendix 1 – Co-development references
Appendix 2 – Resources
Appendix 3 – Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Order Form – Upgrades to subscription access products
Recent report titles from CurrentPartnering
Order Form – Reports
Separate appendix file supplied for:
Appendix 1 – Co-development dealmaking - by financial disclosure
Appendix 2 – Co-development dealmaking - by companies A-Z
Appendix 3 – Co-development dealmaking - by stage of development
Appendix 4 – Co-development dealmaking - by therapeutic target
Appendix 5 – Co-development dealmaking - by technology type
TABLE OF FIGURES
Figure 1: Definition of co-development
Figure 2: Situations where co-development can prove useful
Figure 3: Key components of a co-development deal
Figure 4: Issues in implementing co-development agreements
Figure 5: Trends in co-development deal announcements, 2009-2014
Figure 6: Co-development deals signed at each phase of development, 2009-2013
Figure 7: Co-development agreements – what should a contract include?
Figure 8: Components of the co-development deal structure
Figure 9: Top co-development deals by value since 2009
Figure 10: Most active co-development dealmakers 2009-2014
Figure 11: Bigpharma – top 50 – Co-development deals 2007 to 2013
Figure 12: Bigpharma co-development deal frequency - 2009 to 2014
Figure 13: Online partnering resources
Figure 14: Deal type definitions
$2,995
My Basket
 | Co-development Terms & Agreements in Pharma, Biotech and Diagnostics | $2,995 |
| TOTAL | $2,995 | |
| Empty Cart | ||
| ||
Need Help?
Unsure which report to purchase or have a query regarding a report, please contact us and we'll be glad to help.
Contact our Report Store Team
Email us or call
+44 (0)1904 435190 Europe
+1 (813) 971.8273 US
- Most Viewed